Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and billions on the back end—to apply artificial intelligence to up to ...

(Reuters) - Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

Valo Health, Inc is leveraging artificial intelligence (AI) and advanced analytics to better learn from the patient experience to discover and develop better medicines at greater speed and scale.

Novo Nordisk’s collaboration with artificial intelligence startup Valo Health has focused on developing new drugs for cardiovascular disease. The pharmaceutical giant likes what it’s seen so ...

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop ...

8 January 2025 – Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes ...

Novo Nordisk Expands AI Partnership With Valo Health for Development of Obesity Drugs (Reuters) - Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding ...